文献速递血液净化与透析

血液透析患者接种呼吸道合胞病毒疫苗后体液与细胞免疫延迟但强健

Respiratory syncytial virus vaccination induces delayed but robust humoral and cellular immunity in patients receiving hemodialysis.
PubMed 文献 · Kidney Int · 2026-06-16

结果显示患者IgG于第8周显著升高、第16周达峰,抗体应答较对照延迟,且透析时长与抗体水平负相关;细胞免疫于第2周升高、第8周回落。

要点

  • 血透患者接种Arexvy后抗体应答延迟至第8周才显著升高,第16周达峰。
  • 透析时长与RSV-IgG水平负相关,透析不足1年者抗体滴度更高。
  • RSV特异性CD4+ T细胞第2周升高,以IFN-γ、IL-2或TNF产生为主。

核心结论

  • Arexvy在血液透析患者中可诱导强健的体液和细胞免疫应答。
  • 与肾功能正常对照相比,血透患者抗RSV IgG升高显著延迟。
  • 透析时长可能是该高危人群疫苗效力的关键决定因素。

研究设计与样本

  • 观察性研究,纳入20例接受血液透析并单剂接种Arexvy的患者。
  • 患者中位年龄78.4岁,55%女性,中位透析时长23个月。
  • 基线及第2、5、8、16、32周采血,ELISA定量RSV特异性IgG,多参数流式细胞术评估细胞应答。

主要发现

  • 基线20例中14例血清阳性(IgG>11 SU),中位12.6 SU。
  • IgG至第5周保持稳定,第8周显著升至16.8 SU,第16周达峰17.5 SU,第32周降至14.6 SU但仍高于基线。
  • 健康对照接种Arexvy后第2周RSV-IgG即升高。
  • 抗体水平与透析时长负相关,透析不足1年者滴度显著更高。
  • RSV特异性CD4+ T细胞第2周增加、多产生IFN-γ/IL-2/TNF,第8周回落;浆母细胞第5–8周扩增,转换记忆B细胞早期增加;IL-23、TNF、IL12p70升高,IL-8降低。

临床怎么用

  • 血透患者接种RSV疫苗后抗体应答延迟,评估保护性抗体时宜在接种后第8周以后检测。
  • 透析时长较短(不足1年)者接种后抗体滴度更高,长透析龄患者需关注疫苗应答减弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Respiratory syncytial virus (RSV) causes substantial morbidity in older adults. Patients receiving hemodialysis are particularly vulnerable due to impaired immunity and chronic health care exposure. Data on RSV vaccine immunogenicity in this population are lacking. METHODS: We conducted an observational study of 20 patients receiving hemodialysis (median age 78.4 years; 55% female; median dialysis duration 23 months) who received a single dose of the RSV vaccine Arexvy. Blood samples were obtained at baseline and at weeks two, five, eight, 16, and 32. RSV-specific IgG was quantified by ELISA, and cellular responses were assessed by multiparameter flow cytometry. Fifteen sex- and age-matched individuals with normal kidney function were included as a control group. RESULTS: At baseline, 14 of 20 patients were seropositive (IgG over 11 Standard Units (SU); median 12.6 SU). IgG titters remained stable through week 5, rose significantly at week eight (16.8 SU), peaked at week 16 (17.5 SU), and declined to 14.6 SU at week 32, remaining above baseline. In contrast, healthy control individuals, vaccinated with Arexvv, showed increasing RSV-IgG antibody levels already after two weeks. Antibody levels correlated negatively with dialysis duration, and patients with under one year of dialysis had significantly higher titers. RSV-specific CD4+ T cells increased at week two, with most producing IFN-γ, IL-2, or TNF, and returned to baseline by week eight. B cell responses included expansion of plasmablasts (weeks five-eight) and early increases in switched memory B cells. Cytokine profiling showed modest changes (IL-23, TNF and IL12p70 increased; IL-8 decreased). CONCLUSIONS: Arexvy elicited robust humoral and cellular responses in patients receiving hemodialysis. Attenuated antibody responses with longer dialysis duration suggest dialysis vintage as a key determinant of vaccine efficacy in this high-risk population. The increase in anti-RSV IgG antibody levels was significantly delayed in patients receiving hemodialysis compared with control individuals.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Anft M, Paniskaki K, Franz D, et al. Respiratory syncytial virus vaccination induces delayed but robust humoral and cellular immunity in patients receiving hemodialysis. Kidney Int. 2026. PMID: 42302931. doi:10.1016/j.kint.2026.04.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。